683 related articles for article (PubMed ID: 28169118)
21. Current therapeutic options targeting bone metastasis in metastatic castration resistant prostate cancer.
Fragkoulis C; Gkialas I; Papadopoulos G; Ntoumas K
J BUON; 2016; 21(4):787-791. PubMed ID: 27685897
[TBL] [Abstract][Full Text] [Related]
22. Preventing bone complications in prostate cancer.
Bishr M; Saad F
Curr Opin Support Palliat Care; 2012 Sep; 6(3):299-303. PubMed ID: 22871982
[TBL] [Abstract][Full Text] [Related]
23. The role of bisphosphonates in hormone-refractory prostate cancer.
Saad F; Karakiewicz P; Perrotte P
World J Urol; 2005 Feb; 23(1):14-8. PubMed ID: 15666171
[TBL] [Abstract][Full Text] [Related]
24. [Encounter of cancer cells with bone. Management of bone metastasis arising from prostate cancer].
Kamoto T
Clin Calcium; 2011 Mar; 21(3):465-71. PubMed ID: 21358069
[TBL] [Abstract][Full Text] [Related]
25. New and emerging therapies for bone metastases in genitourinary cancers.
Saylor PJ; Armstrong AJ; Fizazi K; Freedland S; Saad F; Smith MR; Tombal B; Pienta K
Eur Urol; 2013 Feb; 63(2):309-20. PubMed ID: 23201471
[TBL] [Abstract][Full Text] [Related]
26. Treatment and prevention of bone complications from prostate cancer.
Lee RJ; Saylor PJ; Smith MR
Bone; 2011 Jan; 48(1):88-95. PubMed ID: 20621630
[TBL] [Abstract][Full Text] [Related]
27. Management of castration-resistant prostate cancer: bisphosphonates and emerging therapies.
Saad F; Colombel M
Expert Rev Anticancer Ther; 2010 Dec; 10(12):1991-2002. PubMed ID: 21110764
[TBL] [Abstract][Full Text] [Related]
28. Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acid.
Saad F; Segal S; Eastham J
Eur Urol; 2014 Jan; 65(1):146-53. PubMed ID: 22633317
[TBL] [Abstract][Full Text] [Related]
29. Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data.
Ryan CJ; Saylor PJ; Everly JJ; Sartor O
Oncologist; 2014 Oct; 19(10):1012-8. PubMed ID: 25232039
[TBL] [Abstract][Full Text] [Related]
30. Revisiting the role of bone-modifying agents in the management of metastatic prostate cancer.
Cheung FY
Asia Pac J Clin Oncol; 2018 Nov; 14 Suppl 5():13-15. PubMed ID: 30489032
[TBL] [Abstract][Full Text] [Related]
31. Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events.
Smith MR; Coleman RE; Klotz L; Pittman K; Milecki P; Ng S; Chi KN; Balakumaran A; Wei R; Wang H; Braun A; Fizazi K
Ann Oncol; 2015 Feb; 26(2):368-74. PubMed ID: 25425475
[TBL] [Abstract][Full Text] [Related]
32. Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland - the SAKK 95/16 prostate study.
Stoffel ST; von Moos R; Thürlimann B; Cathomas R; Gillessen S; Zürrer-Härdi U; von Briel T; Anchisi S; Feller A; Schär C; Dietrich D; Schwenkglenks M; Lupatsch JE; Mark MT
Swiss Med Wkly; 2021 Mar; 151():w20464. PubMed ID: 33705559
[TBL] [Abstract][Full Text] [Related]
33. Management of bone metastases in refractory prostate cancer--role of denosumab.
Paller CJ; Carducci MA; Philips GK
Clin Interv Aging; 2012; 7():363-72. PubMed ID: 23049248
[TBL] [Abstract][Full Text] [Related]
34. Evidence on the analgesic role of bisphosphonates and denosumab in the treatment of pain due to bone metastases: A systematic review within the European Association for Palliative Care guidelines project.
Porta-Sales J; Garzón-Rodríguez C; Llorens-Torromé S; Brunelli C; Pigni A; Caraceni A
Palliat Med; 2017 Jan; 31(1):5-25. PubMed ID: 27006430
[TBL] [Abstract][Full Text] [Related]
35. A comprehensive review of denosumab for bone metastasis in patients with solid tumors.
Gül G; Sendur MA; Aksoy S; Sever AR; Altundag K
Curr Med Res Opin; 2016; 32(1):133-45. PubMed ID: 26451465
[TBL] [Abstract][Full Text] [Related]
36. Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody.
von Moos R; Costa L; Gonzalez-Suarez E; Terpos E; Niepel D; Body JJ
Cancer Treat Rev; 2019 Jun; 76():57-67. PubMed ID: 31136850
[TBL] [Abstract][Full Text] [Related]
37. Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis.
Saad F; McKiernan J; Eastham J
Urol Oncol; 2006; 24(1):4-12. PubMed ID: 16414486
[TBL] [Abstract][Full Text] [Related]
38. The role of bisphosphonates in the management of prostate cancer.
Saad F
Curr Oncol Rep; 2006 May; 8(3):221-7. PubMed ID: 16618387
[TBL] [Abstract][Full Text] [Related]
39. Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours.
Zheng GZ; Chang B; Lin FX; Xie D; Hu QX; Yu GY; Du SX; Li XD
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 27430483
[TBL] [Abstract][Full Text] [Related]
40. Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: A review.
Cursano MC; Iuliani M; Casadei C; Stellato M; Tonini G; Paganelli G; Santini D; De Giorgi U
Crit Rev Oncol Hematol; 2020 Feb; 146():102864. PubMed ID: 31986318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]